Nalbantoğlu S - Search Results

1

DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.

Kara A, Özgür A, Nalbantoğlu S, Karadağ A. Kara A, et al. Among authors: nalbantoglu s. Mol Biol Rep. 2021 Apr;48(4):3813-3825. doi: 10.1007/s11033-021-06314-z. Epub 2021 Apr 15. Mol Biol Rep. 2021. PMID: 33856604 Review.

2

Metabolomics bridging proteomics along metabolites/oncometabolites and protein modifications: Paving the way toward integrative multiomics.

Nalbantoglu S, Karadag A. Nalbantoglu S, et al. J Pharm Biomed Anal. 2021 May 30;199:114031. doi: 10.1016/j.jpba.2021.114031. Epub 2021 Mar 19. J Pharm Biomed Anal. 2021. PMID: 33857836 Review.

3

Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy.

Nalbantoglu S, Abu-Asab M, Suy S, Collins S, Amri H. Nalbantoglu S, et al. OMICS. 2019 Apr;23(4):214-223. doi: 10.1089/omi.2019.0006. OMICS. 2019. PMID: 31009330 Free PMC article.

4

Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis.

Nalbantoglu S, Abu-Asab M, Tan M, Zhang X, Cai L, Amri H. Nalbantoglu S, et al. OMICS. 2016 Jul;20(7):442-7. doi: 10.1089/omi.2016.0059. OMICS. 2016. PMID: 27428255 Free PMC article.

5

A molecular case report of autosomal dominant retinitis pigmentosa: RP1/RHO sequence variants in a Turkish family.

Nalbantoglu SM, Shahbazov C, Berdeli A. Nalbantoglu SM, et al. OMICS. 2012 Jan-Feb;16(1-2):18-23. doi: 10.1089/omi.2011.0043. OMICS. 2012. PMID: 22321012

6

Comprehensive analysis of a large-scale screen for MEFV gene mutations: do they truly provide a "heterozygote advantage" in Turkey?

Berdeli A, Mir S, Nalbantoglu S, Kutukculer N, Sozeri B, Kabasakal Y, Cam S, Solak M. Berdeli A, et al. Among authors: nalbantoglu s. Genet Test Mol Biomarkers. 2011 Jul-Aug;15(7-8):475-82. doi: 10.1089/gtmb.2010.0146. Epub 2011 Mar 17. Genet Test Mol Biomarkers. 2011. PMID: 21413889

7

Association between RAS gene polymorphisms (ACE I/D, AGT M235T) and Henoch-Schönlein purpura in a Turkish population.

Nalbantoglu S, Tabel Y, Mir S, Serdaroğlu E, Berdeli A. Nalbantoglu S, et al. Dis Markers. 2013;34(1):23-32. doi: 10.3233/DMA-2012-120946. Dis Markers. 2013. PMID: 23151617 Free PMC article.

8

Apoptosis-associated speck-like protein containing a CARD (ASC) expression profiles in familial Mediterranean fever (FMF) patients with different MEFV mutation patterns.

Nalbantoglu S, Tanyolac B, Berdeli A. Nalbantoglu S, et al. Scand J Rheumatol. 2013;42(2):159-62. doi: 10.3109/03009742.2012.699551. Epub 2012 Aug 31. Scand J Rheumatol. 2013. PMID: 22934972

9

Lack of association between macrophage migration inhibitory factor gene promoter (-173 G/C) polymorphism and childhood Henoch-Schönlein purpura in Turkish patients.

Nalbantoglu S, Tabel Y, Mir S, Berdeli A. Nalbantoglu S, et al. Cytokine. 2013 Apr;62(1):160-4. doi: 10.1016/j.cyto.2013.02.024. Epub 2013 Mar 20. Cytokine. 2013. PMID: 23523092

10

FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders.

Ozdemirkiran FG, Nalbantoglu S, Gokgoz Z, Payzin BK, Vural F, Cagirgan S, Berdeli A. Ozdemirkiran FG, et al. Among authors: nalbantoglu s. Arch Med Sci. 2017 Mar 1;13(2):426-432. doi: 10.5114/aoms.2015.53963. Epub 2016 May 31. Arch Med Sci. 2017. PMID: 28261298 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters